Please refer attachment
Awaiting price reaction for this filing.
Piramal Pharma Limited reported audited financial results for Q4 and FY ended March 31, 2025. On a standalone basis, FY25 revenue from operations grew ~20% YoY to Rs. 5,285.71 cr from Rs. 4,390.11 cr, while net profit jumped ~77% to Rs. 691.40 cr from Rs. 391.22 cr. Basic EPS rose to Rs. 5.22 from Rs. 3.05. On a consolidated basis, FY25 revenue rose ~12% to Rs. 9,151.18 cr and net profit grew sharply to Rs. 91.13 cr from Rs. 17.82 cr, though Q4 PAT of Rs. 153.50 cr was weighed down by higher depreciation and tax. The Board recommended a final dividend of Rs. 0.14 per share. Directors Mr. Neeraj Bharadwaj resigned and Mr. Amit Jain (Carlyle nominee) was appointed in his place, while Mr. Jairaj Purandare was re-appointed as Independent Director. Auditor Deloitte Haskins & Sells LLP issued an unmodified opinion.
Strong standalone earnings and robust ~77% PAT growth signal operational improvement, though the modest consolidated profit and a Rs. 44.75 cr intangible asset impairment at a subsidiary indicate mixed picture. The small dividend (Rs. 0.14 per share) is more of a token payout. Overall, results are positive on the standalone business but consolidation-level profitability remains thin.